In recent years, new generation of specific and potent PARP inhibitors in cancer chemotherapy (Coleman et al., 2015; Gunderson & Moore, 2015; Jones et al., 2015; Thomas et al., 2007) provides more selective choices on treating SM injury. Here, PARP1 is linked to cancer.